Anticoagulation for intra-cardiac thrombi in peripartum cardiomyopathy: A review of the literature

Akanksha Agrawal1,∗, Deepanshu Jain2, Pradhum Ram1, Jorge Luis Penalver Leon1 and Janani Rangaswami3

1Department of Internal Medicine, Einstein Medical Center Philadelphia, PA
2Department of Digestive Diseases and Transplantation, Einstein Medical Center Philadelphia, PA
3Division of Nephrology, Department of Internal Medicine, Einstein Medical Center Philadelphia, PA

∗Correspondence: Akanksha21agr@gmail.com (Akanksha Agrawal)

DOI: 10.31083/j.rcm.2019.02.55

This is an open access article under the CC BY-NC 4.0 license [https://creativecommons.org/licenses/by-nc/4.0/]

Peripartum cardiomyopathy is a type of non-ischemic cardiomyopathy with a high rate of thromboembolic events. Guiding strategies for anticoagulation in patients with peripartum cardiomyopathy and thromboembolic events are limited. Literature for all cases of peripartum cardiomyopathy with intracardiac thrombi were reviewed and summarized from twelve case reports. Based on the available literature, we conclude that patients with peripartum cardiomyopathy with ejection fraction of less than 30% should strongly consider anticoagulation therapy to avoid thromboembolic events. Future studies may be able to further elucidate the optimal indication and duration of anticoagulation.

Keywords
Peripartum cardiomyopathy; thrombus; anticoagulation

1. Introduction
Peripartum cardiomyopathy (PPCM) is a relatively rare form of non-ischemic cardiomyopathy that occurs in healthy women during the final month of pregnancy and up to 5 months post-delivery (Johnson-Coyle et al., 2012). According to the National Institutes of Health consensus panel, diagnostic criteria for PPCM includes congestive heart failure symptoms of unknown cause, absence of a pre-existing heart muscle disorder, symptomatic onset during the last month of gestation or 5 months postpartum, and left ventricular systolic dysfunction demonstrated by a decreased ejection fraction (EF) (Pearson et al., 2000). Its incidence in United States varies from 1 in 1300 to 1 in 4000 live births (Elkayam et al., 2001).

In comparison to other forms of cardiomyopathies, PPCM has been associated with higher rates of thromboembolism (Elkayam, 2011). There are several factors during the peripartum period that make expectant mothers hypercoagulable. These factors include cardiac dilation, endothelial injury, and immobility (Azibani and Sliwa, 2018). Studies done by Kolte et al. (2014), show that the most frequent complication in women with PPCM was thromboembolism (6.6%) (Kolte et al., 2014). Given this increased thromboembolic risk, multiple review articles suggest that prophylactic anticoagulation in women with PPCM is advisable, especially when the left ventricular EF is < 35% (Aran and Elkayam, 2016; Azibani and Sliwa, 2018; Pearson et al., 2000). In 2018, the European Society of Cardiology (ESC) updated the guidelines on anticoagulation in pregnancy, recommending that women with PPCM and EF < 25% should receive prophylactic anticoagulation (Level of evidence IIB) (Seeland et al., 2018).

The current review focuses on the use of anticoagulation in patients with PPCM in the setting of known intracardiac thrombi.

2. Methods
An extensive literature search was done using MEDLINE, Google Scholar, and Cochrane review to identify original articles using search words “peripartum cardiomyopathy” and “anticoagulation”. Pertinent studies were manually searched to identify additional relevant studies. Four case reports of patients with intracardiac thrombi and PPCM were excluded since they were in Turkish, French, Senegalese, and Portuguese language (Damorou et al., 2000; Koç et al., 2011; Napporn et al., 2000; Sánchez-Rubio Lezcano et al., 2004; Zehir et al., 2014).

Two case reports by Mikami and Kamiumten (2018) and (LaRue et al., 2011) were excluded because anticoagulation was administered by mechanical circulatory support (MCS) and left ventricular assist device (LVAD), respectively. A case report by Baughman (2006) mentioned the use of prophylactic anticoagulation in a patient with PPCM and no presence of thrombi and hence was excluded. Case reports with deep venous thrombosis or pulmonary embolism in the presence of PPCM were also excluded.

3. Results
A total of 12 original studies were included in our review article. All of these studies were case reports that describe individual cases. The age of women in our study ranged from 20-38 years, mean of 28.1 years. Table 1 describe all the included case reports (Ahuwajri et al., 2012; Bagul et al., 2014; Bhat et al., 1986; Box et al., 2004; Corriveau et al., 2014; Ibebuogu et al., 2007; Kaufman et al., 2003; Kharwar et al., 2014; Kim et al., 2011; Nishi et al., 2002; Sakamoto et al., 2013; Shimamoto et al., 2008).

All except one patient presented during the postpartum period, which ranged from 8 days to 7 months postpartum. One patient was known to have gestational hypertension and eclampsia, while the remaining patients had no previous history of CHF, hyperten-
Table 1. Descriptive summary of case reports (1-12) describing intracardiac thrombi in patients with PPCM.

| Study, Year, Country | Age of patient (years) | Gravidity | Presentation | Mode of delivery | LVEF (%) | LV ED diameter (cm) | Location of thrombus | Appearance/features of thrombus | Anticoagulant used | Clinical outcome | Embolic episode | Days for resolution of thrombus | Follow up EF (%) | LV ED diameter (cm) | Total follow up period |
|----------------------|------------------------|-----------|--------------|------------------|----------|---------------------|----------------------|------------------------------|-------------------|----------------|----------------|-------------------------------|------------------|----------------------|---------------------|
| Nishi et al., 2002 Japan | 23 | 1 | Palpitation, nocturnal dyspnea, orthopnea | 6 weeks PP Vaginal | 18 | 5.7 | Apical thrombi in both ventricle | Spherical, pedunculate, IV heparin → Warfarin | Resolution of thrombus | No | 4 | 2 months | 48 | 4.7 | 1 year |
| Kim et al., 2011 Bangladesh | 22 | N/A | Dyspnea, weakness | 4 months PP Vaginal | 17 | 6.4 | Biventricular thrombi | Larger in the RV, Smaller LV [Septal location] | Subcutaneous Heparin and Warfarin | Resolution of thrombus | No | Smaller LV-16 days, larger RV-21 days | 2 months | 17 | N/A | 2 months |
| Corriveau et al., 2014 Canada | 29 | 3 | Dyspnea, fatigue, orthopnea and LE edema | 2 weeks PP Vaginal | N/A | 6.5 | LV- Large, mobile | Heparin → Warfarin | N/A | Yes-CVA | N/A | 1 year | 62 | 4.8 | 13 months |
| Sakamoto et al., 2013 Japan | 37 | 2 | Dyspnea | 4 months PP C- Section | 29 | 6.5 | 1. LV apex 2. RV apex | Mobile, large [2.8 x 2 cm -Larger LV and 1.6 x 1 cm -RV] | Heparin → Warfarin | Resolution of thrombus | Yes-CVA | N/A | 1 year | 62 | 4.8 | 13 months |
| Bagul et al., 2014 India | 26 | 1 | Dyspnea | 8 days PP Vaginal | 20 | N/A | 1. Apex 2. RV free wall 3. RA Roof | 2.5 x 2 cm, 3.5 x 1 cm, 1 x 1 cm | IV heparin → Warfarin | Resolution of thrombus | No | 2 clots [smaller]-3 days; 1 larger [apex]-1 month | 1 month | 40 | N/A | 1 month |
| Kharwar et al., 2014 India | 30 | 4 | Dyspnea, Orthopnea | 3 weeks PP Vaginal | 32 | 3.05 cm/m2 (LVEDD index) | LV-Septum pedunculated 2.5 x 2 cm | Warfarin | Resolution of thrombus | No | 1 month | 1 month | 43 | N/A | N/A |
| Altuwaijri et al., 2012 Canada | 25 | 4 | Dyspnea, Orthopnea, PND | 7 months PP N/A <20 N/A | LV Apex | N/A | Layered echodense mass | Heparin | Resolution of thrombus | No | 4 days | N/A | N/A | N/A | N/A |
| Box et al., 2004 USA | 31 | N/A | Edema, Fatigue | 4 weeks PP Vaginal | 20 | 6.9 | LV Apex | N/A | N/A | Yes-coronaries | N/A | N/A | N/A | N/A | 6 months |
| Study, Year, Country | Age of patient | Gravidity | Presentation | Mode of delivery | LVEF (%) | LV EDdiameter (cm) | Location of thrombus | Appearance/ features of thrombus | Anticoagulant used | Clinical outcome | Embolic episode | Days for resolution of thrombus | Follow up Echo (%) | LV EDdiameter (cm) | Total follow up period |
|----------------------|----------------|-----------|--------------|------------------|-----------|-------------------|----------------------|-------------------------------|------------------|----------------|--------------|-----------------------------|------------------|------------------|----------------------|
| (Shimamoto et al., 2008), Japan | 32 | 2 | N/A | 10 days post PP, C-section | 6 | 35 X 20 mm | LV apical mural mass → development of 3 LV apical masses → immobile | Warfarin + Heparin → Warfarin | Needed surgical removal as it became mobile | No | 24 days | 30 days | 33 | 5.5 | 2 years |
| (Kaufman et al., 2003), Canada | 38 | 7 | Acute dyspnea, gestation 30 weeks | C-section | 45 | N/A | Lt MCA thrombi | Heparin → Warfarin | Improved clinically | Yes-CVA | N/A | N/A | N/A | N/A | N/A |
| Bebuogu et al., 2007, USA | 24 | 5 | Epigastric, RUQ pain, Nausea, Vomiting | 5 months PP | Vaginal <15 | 6.5 | LV anterior wall thrombus → BiV thrombi | N/A | Yes (not mentioned what kind) | Underwent b/ile thrombectomy | Yes - liver, bilateral kidneys, common iliac and right external iliac arteries | 5 days | N/A | N/A | N/A | 2 weeks |
| Bhat et al., 1986, India | 20 | N/A | Exertional SOB, Fatigue, Palpitation, PND | 4 months PP | Vaginal | 39 | 6.5 | Biventricular apices | Heparin → oral AC | Underwent bilateral femoral thromboembolectomy | Yes - bilateral femoral artery | NA | N/A | N/A | N/A | N/A |
sion, or pregnancy related hypertension (Shimamoto et al., 2008). None of the patients had previous history of thromboembolic episode or family history of hypercoagulable state. One out of 12 patients was antiphospholipid antibody positive after the thrombotic event (Kaufman et al., 2003).

All cases had echocardiographic evidence of an intracardiac thrombus except one, where the patient had a stroke that was presumed to be cardioembolic. Left ventricular ejection fraction (LVEF) varied from < 15% to 45%. Six out of 12 had an embolic episode to the brain (3), coronaries (1), liver and kidney (1), or lower extremity arteries (2). Seven studies that included left ventricular end diastolic diameter (LVEDD) in the case report ranged from 5.7 to 6.9 cm (average 6.4 cm) (normal 3.9-5.3 cm). Seven case reports mentioned the timing of clot resolution, which ranged from 4 days to 1 month. Most studies did not mention the duration of anticoagulation; however, the two that did reported durations of 12 months and lifelong anticoagulation.

4. Discussion

4.1 PPCM and Thromboembolism

Peripartum cardiomyopathy is a form of non-ischemic cardiomyopathy that causes systolic dysfunction in women during the last month of pregnancy or within 5 months post-delivery (Altuwaijri et al., 2012). There are several factors in the coagulation cascade that make the peripartum period hypercoagulable such as increased endogenous thrombin generation, acquired activated protein C resistance, increased levels of coagulation factors VII, VIII, X and plasma fibrinogen, and decreased activated partial thromboplastin time (aPTT) (Hellgren, 2003). These hemostatic changes usually normalize 4-6 weeks after delivery. Additionally, if left ventricular dysfunction persists from PPCM, it leads to blood stasis in the heart making a patient hypercoagulable. In a prospective study from South Africa (n = 100), LV thrombus was found in 16% of the patients with PPCM (Sliwa et al., 2006). In another study by Amos et al (N = 55), 17% of patients developed LV thrombus and none of them had full recovery of LV function (Amos et al., 2006). Kido and Guglin (2019) recently summarized 4 case reports for use of anticoagulation in patient with PPCM with intracardiac thrombi. In our review, we found additional data sources from women with PPCM that developed intracardiac thrombi and received anticoagulation therapy.

4.2 Anticoagulation in PPCM: What do the guidelines say?

Anticoagulation in a patient with PPCM is a topic that lacks extensive medical literature. The guidelines are based on expert opinion and do not delineate clearly the indications for anticoagulation in patients with PPCM. According to the ACCF/AHA guideline in 2013, anticoagulation is recommended for patients with PPCM if ventricular dysfunction is persistent (Writing Committee et al., 2013). However, the terms "ventricular dysfunction" and "persistent" need to be clearly defined. Recently, the guidelines from the ESC 2018 recommend anticoagulation in women with PPCM with LVEF < 25% (level of evidence IIB) (Seeland et al., 2018).

Studies done by Sheppard et al. (2014) referred to the following as indications for anticoagulation in a patients with PPCM: atrial fibrillation, LV thrombus, systemic embolism, bromocriptine use, and EF less than 30%. All except one patient in our review with intracardiac thrombi had EF < 30%. This finding reiterates the possible need for prophylactic anticoagulation or a closer follow up with serial echocardiograms in patients with low EF. Additionally, all the patients in our review who had LV dimensions measured were found to have large left ventricular end diastolic dimension (LVEDD) and mean of 6.4 cm (range 5.7-6.9 cm). These parameters need to be studied further, and may help categorizing patients with PPCM that might benefit from prophylactic anticoagulation.

4.3 Bromocriptine for PPCM and anticoagulation

Bromocriptine, typically used for lactation suppression, continues to be studied for the treatment of PPCM. In a multicenter randomized study by Hilfiker-Kleiner et al. (2017), bromocriptine treatment was associated with high rate of full LV recovery and low morbidity and mortality in PPCM patients compared to PPCM cohorts that are not treated with bromocriptine. Currently, it is not approved by the US Food and Drug Administration (FDA) for treatment of patients with PPCM, but continues to be investigated. There are few case reports suggesting a prothrombotic effect of bromocriptine like cases of myocardial infarction (Hopp et al., 1996; Loewe and Dragovic, 1998). Due to the prothrombotic effect; however, it is advised to implement a full dose of anticoagulation when bromocriptine is used.

4.4 Type and duration of anticoagulant

As discussed above, the first 6-8 weeks postpartum have a persistent hypercoagulable state that requires anticoagulation. Both unfractionated heparin and low molecular weight heparin are safe to use during pregnancy because they do not cross the placenta (Gerald et al., 2009). Due to its shorter half-life and reversible effect, unfractionated heparin is preferred during pregnancy whenever an urgent delivery is suspected due to maternal or fetal instability. Warfarin crosses placenta, and is considered a category D drug for use during pregnancy. In postpartum women, neither warfarin nor heparin is secreted into the breast milk and can be offered during breast-feeding (Gerald et al., 2009). The use of novel oral anticoagulants in pregnancy and embryopathy still has significant data gaps. NOACs have not been reported to be used in the setting of PPCM.

The duration of anticoagulation is another ambiguous topic. As per the heart failure guidelines for PPCM, anticoagulation therapy should be continued until LV function normalizes (Johnson-Coyle et al., 2012). In PPCM patients, it has been reported that 23% to 72% achieve full recovery of normal LV systolic function (McNamara et al., 2015). It occurs within 2 to 6 months of diagnosis, but can be delayed for up to 5 years (Fett et al., 2005). In our review, 7 patients had clot resolution within 1 month, 3 patients required a surgical procedure for thrombectomy, and the remaining two patients lacked data on clot resolution.

4.5 Limitations

Since PPCM with intracardiac thrombi is a rare condition, our systematic review only includes case reports. We rely on the information published and cannot conclude certain aspects because they are not included in the study literature.
5. Conclusion

Thromboembolism is a serious complication in patients with PPCM. Our systematic review summarizes twelve case reports that mentioned the presence of intracardiac thrombi in patients with PPCM. Although this topic lacks well-defined guidelines, we conclude that in patients with PPCM with EF < 30%, anticoagulation should be strongly considered to avoid a thromboembolic event. Future studies with longer follow-up of larger cohorts of patients with PPCM might be able to elucidate further the optimal duration of anticoagulation.

Acknowledgment

Thanks to all the peer reviewers and editors for their opinions and suggestions.

Conflict of Interest

There are no conflicts of interest to declare.

Submitted: May 13, 2019
Accepted: June 20, 2019
Published: June 30, 2019

References

Altuwaijri, W. A., Kirkpatrick, I. D., Jassal, D. S. and Soni, A. (2012) Vanishing left ventricular thrombus in a woman with peripartum cardiomyopathy: a case report. BMC Research Notes 5, 1-3.

Amos, A. M., Jaber, W. A. and Russell, S. D. (2006) Improved outcomes in peripartum cardiomyopathy with contemporary. American Heart Journal 152, 509-513.

Arany, Z. and Elkayam, U. (2016) Peripartum Cardiomyopathy. Circulation 133, 1397–1409.

Azibani, F. and Siwiwa, K. (2018) Peripartum Cardiomyopathy: an Update. Current Heart Failure Reports 15, 297-306.

Bagul, P. K., Phadke, M. S., Pawja, J. S., Sharma, R. B., Lanjewar, C. P. and Kerkar, P. G. (2014) Three vanishing masses in the heart. Journal of Cardiology Cases 10, 19–21.

Baughman, K. L. (2006) Management of a case of peripartum cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine 3, 514-518.

Bhat, P. S., Kakkakayalam, T. S., Shah, R. K., Reddy, M. M. and Narayaran, G. R. (1986) Peripartum cardiomyopathy with biventricular thrombi presenting as acute saddle embolism. A case report. Indian Heart Journal 38, 486-488.

Box, L. C., Hanak, V. and Arciniegas, J. G. (2004) Dual coronary emboli in peripartum cardiomyopathy. Texas Heart Institute Journal 31, 442-444.

Corriveau, S., Cooray, M. and Douketis, J. (2014) To thin or not to thin: A case of peripartum cardiomyopathy. Canadian Journal of Cardiology 30 1.e1-1.e2.

Damorou F.J., Kane A., Napporn G., Thiam O., Bidani A., Diop I.B., Sarr M., Ba S.A. and Diouf S.M. (2000) Biventricular thrombus presenting as acute saddle embolism. A case report. Journal of Forensic Medicine and Pathology 45, 199–201.

Elkayam, U., Tummala, P. P., Rao, K., Akhter, M. W., Karaalip, I. S., Wani, O. R., Hameed, A., Gviazda, I. and Shotan, A. (2001) Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. The New England Journal of Medicine 344, 1567-1571.

Elkayam U. (2011) Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. Journal of the American College of Cardiology 58, 659-670.

Fett, J. D., Christie, L. G., Carraway, R. D. and Murphy, J. G. (2005) Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clinic Proceedings 80, 1602-1606.

Gerald, G., Briggs., Roger, K., Freeman, and Sumner, J. Y. (2009) Drugs in Pregnancy and Lactation (8th Edition), Wolters Kluwer, Philadelphia, PA.

Hellgren, M. (2003) Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 29, 125-130.

Hilfiker-Kleiner, D., Haqhikia, A., Berliner, D., Vogel-Clausen, J., Schwab, J., Franke, A., Schwarzkopf, M., Ehlermann, P., Pfister, R., Westenfeld, G. M. R., Stangl, V., Kindermann, I., Kühl, U., Angermann, C. E., Schiltt, A., Fischer, D., Böhm, E. P. M., Siwiwa, M. and Baversachs, J. (2017) Bromocriptine for the treatment of peripartum cardiomyopathy: a multicenter randomized study. European Heart Journal 38, 2671-2679.

Hopp, L., Haider, B. and Iffy, L. (1996) Myocardial infarction postpartum in patients taking bromocriptine for the prevention of breast engorgement. International Journal of Cardiology 57, 227-232.

Ibebuogu, U. N., Thornton, J. W. and Reed, G. L. (2007) An unusual case of peripartum cardiomyopathy manifesting with multiple thromboembolic phenomenon. Thrombosis Journal 5, 1-5.

Johnson-Coyle, L., Jensen, L. and Sobey, A. (2012) Peripartum cardiomyopathy: review and practice guidelines. American Journal of Critical Care 21, 89-98.

Kaufman, I., Bondy, R. and Benjamin, A. (2003) Peripartum cardiomyopathy and thromboembolism; anesthetic management and clinical course of an obese, diabetic patient. Canadian Journal of Anesthesia 50, 161-165.

Kharwar, R. B., Chandra, S., Dwivedi, S. K. and Saran, R. K. (2014) A pedunculated left ventricular thrombus in a woman with peripartum cardiomyopathy: evaluation by three dimensional echocardiography. J Cardiovasc Ultrasound 22, 139–143.

Kim, D. Y., Islam, S., Mondal, N. T., Mussen, F. and Rauchholz. (2011) Biventricular Thrombi Associated with Peripartum Cardiomyopathy. Journal of Health, Population and Nutrition 29, 178-180.

Kido, K. and Guglin, M. (2019) Anticoagulation therapy in specific cardiomyopathies: isolated left ventricular noncompaction and peripartum cardiomyopathy. Journal of Cardiovascular Pharmacology and Therapeutics 24, 31-36.

Koc, M., Sahin, D. Y., Tekin K. and Cayl, M. (2011) Development of biventricular large apical thrombi and cerebral embolism in young woman in peripartum cardiomyopathy. Türk Kardiyol Dern Arş 39, 591-594.

Kolte, D., Khera, S., Aronow, W. S., Palaniyavami, C., Mujib, M., Ahn, C., Jain, D., Gaus, A., Ahmed, A., Poraza, J. A. and Fonarow, G. C. (2014) Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. Journal of the American Heart Association 3, 1-13.

LaRue, S., Shanks, A., Wang, I., Ewald, G., Anderson, D. and Joseph, S. (2011) Left ventricular Assist Device in Pregnancy. Obstetrics & Gynecology 118, 426-428.

Loewe, C. and Dragovic, L. J. (1998) Acute coronary artery thrombosis in a postpartum woman receiving bromocriptine. The American Journal of Forensic Medicine and Pathology 19, 258-260.

Mcnamara, D. M., Elkayam, U., Alharethi, R., Damp, J., Hsich, E., Ewald, G., Modi, K., Alexes, J. D., Ramani, G. V., Semigran, M. J., Haythe, J., Markham, D. W., Gorcsan, J. 3rd., Wu, J., Halder, I., Pisarcik, J., Cooper, L. T., Fett, J. D. and IPAC Investigators. (2015) Clinical Outcomes for Peripartum Cardiomyopathy in the United States: a Nationwide Population-Based Study. Circulation 131, 905–914.

Mikami, T. and Kamiunten, H. (2018) Emergent caesarian section under mechanical circulatory support for acute severe peripartum cardiomyopathy. Journal of Cardiology Cases 17, 200-203.

Napporn, A. G., Kane, A., Damorou, J. M., Dia, A. A., Diop, I. B., Sarr, M., Bo, S.A. and Diouf, S.M. (2000) Intravenous
thrombosis complicating peri-partum idiopathic myocardopathy. *Annales de Cardiologie et d’ANGEIOLOGIE* 49, 309-314.

Nishi, I., Ishimitsu, T., Ishizu, T., Ueno, Y., Suzuki, A., Seo, Y., Ohtsuka, S., Iida, K. and Yamaguchi, I. (2002) Peripartum Cardiomyopathy and Biventricular thrombi. *Circulation Journal* 66, 863-865.

Pearson, G. D., Veille, J., Rahimtoola, S., Hsia, J., Oakley, C. M., Hosenpud, J. D., Ansari, A. and Baughman, K. L. (2000) Peripartum Cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases [National Institutes of Health] Workshop Recommendations and Review. *JAMA* 283, 1183–1188.

Seeland, U., Bauercass, J., Roos-Hesselink, J. and Regitz-Zagrosek, V. (2018) Update of the ESC guidelines 2018 on cardiovascular diseases during pregnancy: Most important facts. *Herz* 43, 710-718.

Sánchez-Rubio Lezcano J., Galache Osuna J.G., Marquina Barcos A., Calvo Cebollero I., Diarte de Miguel J.A. and Placer Peralta L.J. (2004) Peripartum cardiomyopathy with biventricular thrombi. *Anales de Medicina Interna* 21, 498–500.

Sakamoto, A., Hosoya, N., Kageyama, S., Yoshizaki, T., Takeuchi, R., Murata, K., Nawada, R., Onodera, T., Takizawa, A., Nonaka, Y. and Fukasawa, S. (2013) Peripartum cardiomyopathy with biventricular thrombus which led to massive cerebral embolism. *Journal of Cardiology Cases* 9, 71–74.

Shimamoto, T., Marui, A., Oda, M., Tomita, S., Nakajima, H., Takeuchi, T. and Komeda, M. (2008) A case of peripartum cardiomyopathy with recurrent left ventricular apical thrombus. *Circulation Journal* 72, 853–854.

Sliwa, K., Forster, O. and Lishober, E. (2006) Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. *European Heart Journal* 27, 441–446.

Sheppard, R., Rajagopalan, N., Safirstein, J. and Briller, J. (2014) An update on treatments and outcomes in peripartum cardiomyopathy. *Future Cardiology* 10, 435–447.

Writing Committee, M., Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey DE, J. r., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., Johnson, M. R., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., McMurtry, J. J., Mitchell, J. E., Peterson, P. N., Riegel, B., Sam, F., Stevenson, L.W., Tang, W. H., Tsai, E. J. and Wilkoff, B. L., American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. [2013] 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 128, e240–e327.

Zehir, R., Karabay, C. Y., Kocabay, G., Kalayci, A., Akgun, T. and Kırma, C. (2014) An unusual presentation of peripartum cardiomyopathy: recurrent transient ischemic attacks. *Revista Portuguesa de Cardiologia* 33, 561.e1-561.e3